Markets are assessing the reshaped US trade landscape after Trump on Thursday laid out steep new tariffs for dozens of ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor ...

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

While the stock market has been on a strong winning streak recently, you should only be putting cash into stocks that you ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...

Trump gave the companies 60 days to voluntarily comply, threatening to "deploy every tool in our arsenal to protect American ...

President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ...

In 17 identical letters posted to his Truth Social account, the president said companies must lower their prices or the ...